Novo Nordisk (NVO)
(Delayed Data from NYSE)
$111.94 USD
-0.01 (-0.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.94 USD
-0.01 (-0.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Zacks News
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Novo Nordisk (NVO) Catches Eye: Stock Jumps 7.2%
by Zacks Equity Research
Novo Nordisk (NVO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.
SNY or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Q3 Earnings Scorecard and Top Research Reports for Apple, PepsiCo & McDonald's
by Sheraz Mian
Today's Research Daily features Q3 earnings season scorecard and new research reports on Apple (AAPL), PepsiCo (PEP) and McDonald's (MCD) and others.
Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.
Novo Nordisk Raises Sales & Operating Profit Outlook for 2020
by Zacks Equity Research
Novo Nordisk (NVO) raises 2020 sales and operating profit outlook at constant exchange rates.
The Zacks Analyst Blog Highlights: JPM, PYPL, NVO, RHHBY and TM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPM, PYPL, NVO, RHHBY and TM
SNY vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
Top Analyst Reports for JPMorgan, PayPal & Novo Nordisk
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), PayPal (PYPL) and Novo Nordisk (NVO).
Lilly Drug Gets Fast Track to Improve Heart Attack Outcome
by Zacks Equity Research
Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.
The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY
Top Research Reports for Disney, Novo Nordisk & BHP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Novo Nordisk (NVO) and BHP Group (BHP).
Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity
by Zacks Equity Research
Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.
Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates
by Kinjel Shah
Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).
Novo Nordisk (NVO) Resumes Phase III Hemophilia Studies
by Zacks Equity Research
Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.
Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.
Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio
by Zacks Equity Research
Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.
Top Stock Reports for Alphabet, Merck & Medtronic
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Merck (MRK) and Medtronic (MDT).
Novo Nordisk Completes Two Studies on Obesity Candidate
by Zacks Equity Research
Novo Nordisk (NVO) provides data from a monotherapy study and a combination study on AM833.
Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study
by Zacks Equity Research
Merck's (MRK) type 2 diabetes drug, Steglatro, achieves primary endpoint of non-inferiority in major adverse CV events compared to placebo in a late-stage cardiovascular outcomes study.
Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals
by Kinjel Shah
J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.
3 Diabetes Management Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments